STOCKHOLM, March 31, 2016 /PRNewswire/ --
Elekta announced today the formation of a multiyear strategic partnership with GenesisCare, the largest provider of radiotherapy in Australia. The deal, over eight years, is valued at more than USD 100 million. No part of the agreement will be booked in Q4 of this fiscal year.
The partnership includes the acquisition of solutions across Elekta's portfolio, including Leksell Gamma Knife® Icon™ radiosurgery systems, Versa HD™ linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by GenesisCare cancer treatment centers in Australia, the UK and new markets.
GenesisCare is also expected to order Elekta's high-field (1.5 Tesla) MRI-guided linear accelerator (MR-linac*) when this new treatment technology is available in the market in 2017.
GenesisCare's ambition is to transform health care and improve outcomes for cancer patients globally. A key enabler is the harmonization of its enterprise-wide practices and enhanced cancer management technology available for its highly skilled medical teams.
"We are proud to partner alongside GenesisCare and support their exciting vision," says Tomas Puusepp, President and CEO of Elekta. "By choosing Elekta, GenesisCare will receive the most advanced and recognized cancer treatment solutions on the market. Both Leksell Gamma Knife and Versa HD are known for their extreme accuracy, efficiency and outstanding outcomes. We are looking forward to being GenesisCare's partner as they expand into new markets.
GenesisCare Managing Director, Dan Collins, says: "Elekta is a natural partner for GenesisCare. We want all cancer patients to receive rapid access to high quality care. Elekta helps us make this happen with their suite of technology solutions, global reach and commitment to innovation.
"The MR-linac is a game changer," he adds. "We expect cancer patients, including those receiving treatment for prostate, breast and other cancers, to benefit from this innovation. Anything that improves the accuracy of treatment and provides a smoother patient experience should improve outcomes."
Software systems included in the agreement comprise MOSAIQ® enterprise licensing, which provides a full-featured OIS to enable a completely optimized, automated workflow across their entire global enterprise - to fulfill the organization's "Cancer Services of the Future" vision. The deal also includes METRIQ®, a fully integrated cancer registry for data collection and follow-up through reporting and analysis.
*Elekta's MR-linac is a works in progress and not yet available for sale or distribution in Australia or the UK.
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on March 31, 2016.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: http://www.elekta.com
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Time zone: CET: Central European Time